Usefulness of omalizumab in ten patients with severe occupational asthma.
Allergy
; 68(6): 813-5, 2013 Jun.
Article
em En
| MEDLINE
| ID: mdl-23647648
ABSTRACT
BACKGROUND:
The management of severe occupational asthma (OA) remains problematic and new alternative treatments providing better disease control are required, ideally enabling affected individuals to remain in their job.METHODS:
Ten patients with severe uncontrolled OA were treated with the monoclonal anti-IgE antibody omalizumab. In six cases the causative agent was a high molecular weight (HMW) compound and in four cases it was a low molecular weight (LMW) chemical. All of the patients had well documented OA despite workplace adjustments.RESULTS:
During treatment, nine patients exhibited a lower rate of asthma exacerbations and used less oral or inhaled corticosteroids. Seven patients were able to continue working at the same workplace as before treatment.CONCLUSION:
We have demonstrated that omalizumab is a potential treatment for severe uncontrolled OA and enabled seven of the ten patients in the study to remain in their job.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Anticorpos Anti-Idiotípicos
/
Antiasmáticos
/
Asma Ocupacional
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Evaluation_studies
/
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Allergy
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
França